Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology and Therapeutics
|
June 15, 2019
Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
Felix Huth, Anne Gardin, Kenichi Umehara, et al.
Pharmaceutical Research
|
June 24, 2026
Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans
Mitesh Patel, Sahil Shaikh, Felix Huth, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 22, 2022
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier
Paul W Manley, Felix Huth, Saliha Moussaoui, et al.
Pharmaceutics
|
October 29, 2025
Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib
Ioannis Loisios-Konstantinidis, Felix Huth, Matthias Hoch, et al.
Journal of Pharmaceutical Sciences
|
March 10, 2026
Navigating ADME profiling challenges in microphysiological systems: Evaluation of a liver-chip model for clearance prediction
Lina Mettler, Julia Riede, Felix Huth, et al.
Biopharmaceutics & Drug Disposition
|
February 17, 2018
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
Ken-Ichi Umehara, Felix Huth, Christina S Won, et al.
Clinical and Translational Science
|
September 17, 2024
Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives
Felix Huth, Ulrike Glaenzel, Anton Drollmann, et al.
European Journal of Clinical Pharmacology
|
December 24, 2017
In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
Yi Jin, Hubert Borell, Anne Gardin, et al.
European Journal of Clinical Pharmacology
|
August 9, 2019
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
Anne Gardin, Kasra Shakeri-Nejad, Andrea Feller, et al.
Drug Metabolism and Personalized Therapy
|
November 28, 2017
Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method
Ken-Ichi Umehara, Felix Huth, Helen Gu, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology and Therapeutics
|
June 15, 2019
Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations
Felix Huth, Anne Gardin, Kenichi Umehara, et al.
Pharmaceutical Research
|
June 24, 2026
Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans
Mitesh Patel, Sahil Shaikh, Felix Huth, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 22, 2022
A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier
Paul W Manley, Felix Huth, Saliha Moussaoui, et al.
Pharmaceutics
|
October 29, 2025
Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib
Ioannis Loisios-Konstantinidis, Felix Huth, Matthias Hoch, et al.
Journal of Pharmaceutical Sciences
|
March 10, 2026
Navigating ADME profiling challenges in microphysiological systems: Evaluation of a liver-chip model for clearance prediction
Lina Mettler, Julia Riede, Felix Huth, et al.
Biopharmaceutics & Drug Disposition
|
February 17, 2018
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
Ken-Ichi Umehara, Felix Huth, Christina S Won, et al.
Clinical and Translational Science
|
September 17, 2024
Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives
Felix Huth, Ulrike Glaenzel, Anton Drollmann, et al.
European Journal of Clinical Pharmacology
|
December 24, 2017
In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
Yi Jin, Hubert Borell, Anne Gardin, et al.
European Journal of Clinical Pharmacology
|
August 9, 2019
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
Anne Gardin, Kasra Shakeri-Nejad, Andrea Feller, et al.
Drug Metabolism and Personalized Therapy
|
November 28, 2017
Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition method
Ken-Ichi Umehara, Felix Huth, Helen Gu, et al.
Page
of 5